vs

Side-by-side financial comparison of Certara, Inc. (CERT) and Immunocore Holdings plc (IMCR). Click either name above to swap in a different company.

Certara, Inc. is the larger business by last-quarter revenue ($106.9M vs $104.5M, roughly 1.0× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 0.8%). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs 7.0%).

Certara is a global leader in biopharmaceutical software and consulting services, specializing in modeling, simulation, and regulatory science solutions. It serves pharmaceutical companies, biotech firms and healthcare stakeholders across all drug development stages, helping accelerate new therapy launches, lower R&D risks and cut overall development costs.

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

CERT vs IMCR — Head-to-Head

Bigger by revenue
CERT
CERT
1.0× larger
CERT
$106.9M
$104.5M
IMCR
Growing faster (revenue YoY)
IMCR
IMCR
+23.5% gap
IMCR
24.3%
0.8%
CERT
Faster 2-yr revenue CAGR
IMCR
IMCR
Annualised
IMCR
21.7%
7.0%
CERT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CERT
CERT
IMCR
IMCR
Revenue
$106.9M
$104.5M
Net Profit
$-8.8M
Gross Margin
61.1%
97.4%
Operating Margin
34.9%
-18.8%
Net Margin
-8.2%
Revenue YoY
0.8%
24.3%
Net Profit YoY
-287.2%
EPS (diluted)
$-0.06
$-0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CERT
CERT
IMCR
IMCR
Q1 26
$106.9M
Q4 25
$103.6M
$104.5M
Q3 25
$104.6M
$103.7M
Q2 25
$104.6M
$98.0M
Q1 25
$106.0M
$93.9M
Q4 24
$100.4M
$84.1M
Q3 24
$94.8M
$80.2M
Q2 24
$93.3M
$75.4M
Net Profit
CERT
CERT
IMCR
IMCR
Q1 26
$-8.8M
Q4 25
$-5.9M
Q3 25
$1.5M
$-177.0K
Q2 25
$-2.0M
$-10.3M
Q1 25
$4.7M
$5.0M
Q4 24
$6.6M
Q3 24
$-1.4M
$8.7M
Q2 24
$-12.6M
$-11.6M
Gross Margin
CERT
CERT
IMCR
IMCR
Q1 26
61.1%
Q4 25
97.4%
Q3 25
99.5%
Q2 25
98.9%
Q1 25
99.1%
Q4 24
99.6%
Q3 24
99.4%
Q2 24
97.7%
Operating Margin
CERT
CERT
IMCR
IMCR
Q1 26
34.9%
Q4 25
0.8%
-18.8%
Q3 25
2.9%
-6.9%
Q2 25
9.1%
-15.2%
Q1 25
7.2%
-3.9%
Q4 24
6.0%
-23.1%
Q3 24
2.7%
-10.6%
Q2 24
-9.7%
-21.2%
Net Margin
CERT
CERT
IMCR
IMCR
Q1 26
-8.2%
Q4 25
-5.7%
Q3 25
1.5%
-0.2%
Q2 25
-1.9%
-10.5%
Q1 25
4.5%
5.4%
Q4 24
6.6%
Q3 24
-1.4%
10.9%
Q2 24
-13.5%
-15.4%
EPS (diluted)
CERT
CERT
IMCR
IMCR
Q1 26
$-0.06
Q4 25
$-0.04
$-0.61
Q3 25
$0.01
$0.00
Q2 25
$-0.01
$-0.20
Q1 25
$0.03
$0.10
Q4 24
$0.04
$-0.47
Q3 24
$-0.01
$0.17
Q2 24
$-0.08
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CERT
CERT
IMCR
IMCR
Cash + ST InvestmentsLiquidity on hand
$149.5M
$864.2M
Total DebtLower is stronger
$3.0M
Stockholders' EquityBook value
$1.0B
$381.0M
Total Assets
$1.5B
$1.1B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CERT
CERT
IMCR
IMCR
Q1 26
$149.5M
Q4 25
$189.4M
$864.2M
Q3 25
$172.7M
$892.4M
Q2 25
$162.3M
$882.8M
Q1 25
$179.1M
$837.0M
Q4 24
$179.2M
$820.4M
Q3 24
$233.0M
$901.3M
Q2 24
$224.6M
$859.6M
Total Debt
CERT
CERT
IMCR
IMCR
Q1 26
$3.0M
Q4 25
$293.1M
Q3 25
$293.5M
Q2 25
$294.2M
Q1 25
$294.8M
Q4 24
$295.4M
Q3 24
$296.1M
$438.7M
Q2 24
$296.7M
$452.5M
Stockholders' Equity
CERT
CERT
IMCR
IMCR
Q1 26
$1.0B
Q4 25
$1.1B
$381.0M
Q3 25
$1.1B
$396.6M
Q2 25
$1.1B
$388.5M
Q1 25
$1.1B
$378.5M
Q4 24
$1.1B
$360.7M
Q3 24
$1.1B
$377.8M
Q2 24
$1.0B
$359.1M
Total Assets
CERT
CERT
IMCR
IMCR
Q1 26
$1.5B
Q4 25
$1.6B
$1.1B
Q3 25
$1.5B
$1.1B
Q2 25
$1.5B
$1.1B
Q1 25
$1.6B
$1.0B
Q4 24
$1.6B
$1.0B
Q3 24
$1.5B
$1.1B
Q2 24
$1.5B
$1.0B
Debt / Equity
CERT
CERT
IMCR
IMCR
Q1 26
0.00×
Q4 25
0.28×
Q3 25
0.28×
Q2 25
0.27×
Q1 25
0.27×
Q4 24
0.28×
Q3 24
0.28×
1.16×
Q2 24
0.28×
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CERT
CERT
IMCR
IMCR
Operating Cash FlowLast quarter
$11.7M
$-32.7M
Free Cash FlowOCF − Capex
$-35.5M
FCF MarginFCF / Revenue
-34.0%
Capex IntensityCapex / Revenue
0.6%
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CERT
CERT
IMCR
IMCR
Q1 26
$11.7M
Q4 25
$28.8M
$-32.7M
Q3 25
$32.3M
$-4.5M
Q2 25
$17.8M
$26.0M
Q1 25
$17.4M
$435.0K
Q4 24
$49.4M
$-14.0M
Q3 24
$17.0M
$21.1M
Q2 24
$9.8M
$23.5M
Free Cash Flow
CERT
CERT
IMCR
IMCR
Q1 26
Q4 25
$27.8M
$-35.5M
Q3 25
$32.1M
$-5.2M
Q2 25
$17.8M
$25.6M
Q1 25
$16.8M
$137.0K
Q4 24
$49.0M
$-17.5M
Q3 24
$16.8M
$20.3M
Q2 24
$9.4M
$23.1M
FCF Margin
CERT
CERT
IMCR
IMCR
Q1 26
Q4 25
26.8%
-34.0%
Q3 25
30.7%
-5.0%
Q2 25
17.0%
26.1%
Q1 25
15.8%
0.1%
Q4 24
48.8%
-20.9%
Q3 24
17.7%
25.3%
Q2 24
10.1%
30.7%
Capex Intensity
CERT
CERT
IMCR
IMCR
Q1 26
0.6%
Q4 25
1.0%
2.8%
Q3 25
0.2%
0.7%
Q2 25
0.1%
0.4%
Q1 25
0.6%
0.3%
Q4 24
0.4%
4.3%
Q3 24
0.2%
1.0%
Q2 24
0.5%
0.4%
Cash Conversion
CERT
CERT
IMCR
IMCR
Q1 26
Q4 25
Q3 25
21.19×
Q2 25
Q1 25
3.66×
0.09×
Q4 24
7.51×
Q3 24
2.42×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons